Importantly, rosiglitazone, one agonist of PPAR-gamma, substantially restored phenotypes resulting from Seipin deficiency, such as aberrant LDs, reduced sphingolipids, obstructed OPC differentiation, and neurobehavioral defects. The gene discussed is PPARG; the disease is hyperinsulinemic hypoglycemia, familial, 4.